Top Page
Icecure Medical
(NASDAQ:ICCM)
Icecure Medical (ICCM) vs. SPDR S&P 500 ETF (SPY)
Icecure Medical Business Overview & Revenue Model
Icecure Medical Earnings Call Summary
Icecure Medical Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 2.79M | 3.29M | 3.23M | 3.08M | 4.14M | 4.08M |
| Gross Profit | 1.00M | 1.45M | 1.30M | 1.45M | 2.19M | 2.66M |
| EBITDA | -15.54M | -15.36M | -15.25M | -16.49M | -9.60M | -4.08M |
| Net Income | -15.58M | -15.32M | -14.65M | -17.22M | -10.07M | ― |
Balance Sheet | ||||||
| Total Assets | 10.59M | 12.58M | 16.41M | 30.19M | 32.28M | 10.34M |
| Cash, Cash Equivalents and Short-Term Investments | 5.38M | 7.56M | 11.06M | 23.66M | 25.62M | 3.50M |
| Total Debt | 2.37M | 459.00K | 599.00K | 597.00K | 909.00K | 301.04K |
| Total Liabilities | 7.70M | 5.67M | 4.25M | 4.77M | 5.32M | 5.75M |
| Stockholders Equity | 2.89M | 6.90M | 12.16M | 25.42M | 26.96M | 4.58M |
Cash Flow | ||||||
| Free Cash Flow | -14.26M | -12.63M | -13.00M | -15.18M | -13.14M | ― |
| Operating Cash Flow | -14.20M | -12.56M | -12.52M | -14.29M | -12.61M | ― |
| Investing Cash Flow | 770.00K | 446.00K | -713.00K | -891.00K | 3.79M | ― |
| Financing Cash Flow | 9.11M | 9.19M | 83.00K | 13.58M | 30.89M | 5.95M |
Icecure Medical Technical Analysis
Icecure Medical Risk Analysis
Icecure Medical Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
67 Neutral | 95.53M | 12.35 | 4.83% | ― | 1.43% | -19.78% | |
57 Neutral | 113.94M | -2.75 | -83.03% | ― | -9.59% | 8.78% | |
52 Neutral | 84.69M | -18.18 | -9.44% | ― | 15.16% | -39.18% | |
51 Neutral | $72.13M | ― | -230.80% | ― | -16.46% | 4.14% | |
49 Neutral | 102.22M | -2.94 | -88.69% | ― | 7.60% | -0.78% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
Icecure Medical Corporate Events
On September 15, 2025, IceCure Medical announced it received regulatory approval in Israel for its next-generation XSense™ Cryoablation System, which is designed for treating breast cancer and other medical indications. This approval by Israel’s Ministry of Health reinforces IceCure’s leadership in cryoablation technology and is expected to enhance the company’s market position by offering a minimally invasive treatment option that reduces costs and accelerates recovery for patients.
On September 1, 2025, IceCure Medical Ltd. held a Special General Meeting of Shareholders where all agenda items were approved by the shareholders. This approval is significant as it aligns with the company’s strategic plans and potentially impacts its operational and market strategies, reflecting shareholder support for its ongoing initiatives.
On September 4, 2025, IceCure Medical announced promising results from an independent study on their ProSense® cryoablation technology for treating abdominal wall endometriosis (AWE). Conducted at Nîmes University Hospital, the study showed significant pain reduction and high procedural efficacy, with median pain scores dropping from 8 to 0. The study supports ProSense® as a safe, effective, and minimally invasive treatment option, enhancing its commercial potential and industry positioning.
On August 20, 2025, IceCure Medical Ltd. held its Annual and Special General Meeting of Shareholders, where all agenda items were approved by the required majority. This approval signifies strong shareholder support for the company’s strategic direction and could impact its future operations and market positioning.
On August 13, 2025, IceCure Medical Ltd. released its financial and operational results for the first half of 2025. The company reported a decrease in revenues to $1.25 million from $1.75 million in the same period of 2024, alongside a net loss of $6.95 million. Despite the financial challenges, IceCure continues to focus on expanding its market presence and advancing its cryoablation technology, which may have implications for its stakeholders and industry positioning.
On August 1, 2025, IceCure Medical announced the closing of its rights offering, which expired on July 28, 2025. The offering was approximately two times oversubscribed, resulting in the issuance of nearly 10 million ordinary shares and warrants, raising gross proceeds of approximately $10 million. The proceeds are intended for repaying a bridge loan and for general corporate purposes. This successful capital raise is expected to strengthen IceCure’s financial position and support its ongoing operations and market expansion efforts.
IceCure Medical Ltd. has announced a Special General Meeting of Shareholders scheduled for September 1, 2025, to appoint Mr. Yonatan Malca as an external director for a three-year term. Shareholders of record as of August 4, 2025, are eligible to vote on the proposal, which the Board of Directors unanimously recommends. The meeting will be held remotely, and shareholders can vote either in person or by proxy. This meeting is significant as it involves the appointment of a new director, which could influence the company’s strategic direction and governance.
IceCure Medical announced its participation in the 33rd Annual Meeting of the Japanese Breast Cancer Society Conference in July 2025, showcasing the ProSense® system’s effectiveness in breast cancer treatment. The conference highlighted positive clinical data, including a 99% recurrence-free rate with cryoablation, and awarded the Best of Breast Cancer award to an independent study demonstrating zero local recurrence. This positions IceCure for potential regulatory approval and commercial adoption in Japan, enhancing its market presence.
IceCure Medical Ltd. has announced its upcoming Annual and Special General Meeting of Shareholders, scheduled for August 20, 2025. The meeting will address several key agenda items, including the re-appointment of the company’s independent auditor and directors, as well as a discussion on the company’s financial statements for the year ended December 31, 2024. The board of directors recommends voting in favor of the proposed resolutions, which could impact the company’s governance and operational strategies moving forward.
IceCure Medical announced preliminary unaudited financial results for the first half of 2025, revealing lower product sales due to delayed shipments and the absence of revenue from a previous agreement with Terumo Corporation in Japan. The company expects a higher net loss compared to the same period in 2024, although operating expenses are not anticipated to be materially affected. Additionally, IceCure commenced a rights offering on July 10, 2025, aiming to raise $10 million by allowing shareholders to purchase units comprising shares and warrants. The proceeds will be used to repay a bridge loan and for general corporate purposes. Epoch Partner Investments Limited, the largest shareholder, has committed to fully participate in the offering.
On July 3, 2025, IceCure Medical announced its preliminary financial results for the three and six months ending June 30, 2025. The company reported product sales of approximately $525,000 for the three-month period, with some shipments delayed due to geopolitical tensions but expected to be completed in July. The six-month sales totaled around $1.25 million, a decrease from the previous year. Despite these challenges, IceCure’s operations in the U.S. remained unaffected due to adequate inventory. The company plans to release comprehensive financial results in August 2025.
On June 25, 2025, IceCure Medical announced a rights offering to raise up to $10 million, allowing shareholders to purchase additional units of the company’s stock. The offering, which includes participation from its largest shareholder, Epoch Partner Investments Limited, aims to repay a bridge loan and support corporate and working capital needs. The subscription rights expire on July 28, 2025, and the company has engaged Maxim Group LLC as the dealer-manager for this offering.